Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Tóm tắt
Chemotherapy plays an important role in the management of metastatic breast cancer. The anthracyclines (doxorubicin, epirubicin) and the taxanes (paclitaxel, docetaxel) are considered the most active agents for patients with advanced breast cancer. Traditionally, the anthracyclines have been used in combination with cyclophosphamide and 5-fluorouracil (FAC, FEC). The taxanes have single-agent activity similar to older combination chemotherapy treatments. There is great interest in developing anthracycline/taxane combinations. Capecitabine is indicated for patients who progress after anthracycline and taxane therapy. Vinorelbine and gemcitabine have activity in patients with metastatic breast cancer and are commonly used as third- and fourth-line palliative therapy. The role of high-dose chemotherapy is not well-defined and remains experimental. Novel cytotoxic therapy strategies include the development of anthracycline, taxane, and oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, and multidrug resistance inhibitors.
A better understanding of the biology of breast cancer is providing novel treatment approaches. Oncogenes and tumor-supressor genes are emerging as important targets for therapy. Trastuzumab, a monoclonal antibody directed against the Her-2/neu protein, has been shown to prolong survival in patients with metastatic breast cancer. Other novel biologic therapies interfere with signal transduction pathways and angiogenesis. The challenge for the next decade will be to integrate these promising agents in the management of metastatic and primary breast cancer.
Từ khóa
Tài liệu tham khảo
Esteva, 1999, Adjuvant systemic therapy for primary breast cancer, Surg Clin North Am, 79, 1075, 10.1016/S0039-6109(05)70062-1
Henderson, 1991, Breast Diseases, 604
Ellis, Diseases of the Breast
Greenberg, 1996, Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, J Clin Oncol, 14, 2197, 10.1200/JCO.1996.14.8.2197
Greenspan, 1965, Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma, J Mt Sinai Hosp NY, 32, 1
Hortobagyi, 1979, Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG, Cancer, 43, 1225, 10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6
A'Hern, 1993, Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens, Br J Cancer, 67, 801, 10.1038/bjc.1993.146
Bull, 1978, A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy, Cancer, 41, 1649, 10.1002/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J
Smalley, 1977, A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group Project, Cancer, 40, 625, 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
Muss, 1978, Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer, Cancer, 42, 2142, 10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3
Tormey, 1984, A comparison of intermittent vs. continuous use of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: a Cancer and Leukemia Group B Study, Am J Clin Oncol (CCT), 7, 231, 10.1097/00000421-198406000-00007
Aisner, 1987, Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B, J Clin Oncol, 5, 1523, 10.1200/JCO.1987.5.10.1523
Uziely, 1995, Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies, J Clin Oncol, 13, 1777, 10.1200/JCO.1995.13.7.1777
Lyass, 2000, Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma, Cancer, 89, 1037, 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Ranson, 1997, Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial, J Clin Oncol, 15, 3185, 10.1200/JCO.1997.15.10.3185
Shapiro, 1999, Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group, J Clin Oncol, 17, 1435, 10.1200/JCO.1999.17.5.1435
Valero, 1999, Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer, J Clin Oncol, 17, 1425, 10.1200/JCO.1999.17.5.1425
Camaggi, 1993, Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study, Cancer Chemother Pharmacol, 32, 301, 10.1007/BF00686176
Plosker, 1993, Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy, Drugs, 45, 788, 10.2165/00003495-199345050-00011
French Epirubicin Study Group, 1988, A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin, J Clin Oncol, 6, 679, 10.1200/JCO.1988.6.4.679
French Epirubicin Study Group, 1991, A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients, J Clin Oncol, 9, 305, 10.1200/JCO.1991.9.2.305
French Epirubicin Study Group, 2000, Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment, J Clin Oncol, 18, 3115, 10.1200/JCO.2000.18.17.3115
Schiff, 1979, Promotion of microtubule assembly in vitro by Taxol, Nature, 277, 665, 10.1038/277665a0
Haldar, 1995, Inactivation of Bcl-2 by phosphorylation, Proc Natl Acad Sci USA, 92, 4507, 10.1073/pnas.92.10.4507
Haldar, 1997, Bcl2 is the guardian of microtubule integrity, Cancer Res, 57, 229
Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J Am Chem Soc, 93, 2325, 10.1021/ja00738a045
Holmes, 1991, Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J Natl Cancer Inst, 83, 1797, 10.1093/jnci/83.24.1797-a
Holmes, 1993, The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer, J Natl Cancer Inst Monogr, 15, 161
Seidman, 1995, Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response, J Clin Oncol, 13, 1152, 10.1200/JCO.1995.13.5.1152
Abrams, 1995, Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial, J Clin Oncol, 13, 2056, 10.1200/JCO.1995.13.8.2056
Nabholtz, 1996, Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer, J Clin Oncol, 14, 1858, 10.1200/JCO.1996.14.6.1858
1998, Product information: paclitaxel (Taxol), Bristol Myers-Squibb
Smith, 1999, Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26, J Clin Oncol, 17, 3403, 10.1200/JCO.1999.17.11.3403
Winer, 1998, Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342, Proc Am Soc Clin Oncol, 17, 101a
Bishop, 1999, Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer, J Clin Oncol, 17, 2355, 10.1200/JCO.1999.17.8.2355
Paridaens, 2000, Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over, J Clin Oncol, 18, 724, 10.1200/JCO.2000.18.4.724
Sledge, 1997, Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: an Intergroup trial, Proc Am Soc Clin Oncol, 16, 2a
Verweij, 1994, Paclitaxel (Taxol) and Docetaxel (Taxotere): not simply two of a kind, Ann Oncol, 5, 495, 10.1093/oxfordjournals.annonc.a058903
Valero, 1997, Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy, Semin Oncol, 24, S13
Ravdin, 1995, Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer, J Clin Oncol, 13, 2879, 10.1200/JCO.1995.13.12.2879
Valero, 1995, Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer, J Clin Oncol, 13, 2886, 10.1200/JCO.1995.13.12.2886
Nabholtz, 1999, Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group, J Clin Oncol, 17, 1413, 10.1200/JCO.1999.17.5.1413
Sjostrom, 1999, Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group, Eur J Cancer, 35, 1194, 10.1016/S0959-8049(99)00122-7
Chan, 1999, Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group, J Clin Oncol, 17, 2341, 10.1200/JCO.1999.17.8.2341
Valero, 1998, A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer, J Clin Oncol, 16, 3362, 10.1200/JCO.1998.16.10.3362
Seidman, 1999, Single-agent paclitaxel in the treatment of breast cancer: phase I and II development, Semin Oncol, 26, 14
Perez, 1999, A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer, Proc Am Soc Clin Oncol, 18, 480a
Fumoleau, 1995, Current status of Taxotere (docetaxel) as a new treatment in breast cancer, Breast Cancer Res Treat, 33, 39, 10.1007/BF00666069
Burstein, 2000, Docetaxel administered on a weekly basis for metastatic breast cancer, J Clin Oncol, 18, 1212, 10.1200/JCO.2000.18.6.1212
Blum, 1999, Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer, J Clin Oncol, 17, 485, 10.1200/JCO.1999.17.2.485
O'Shaughnessy, 1998, A randomized phase II study of Xeloda™ (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged 55 years, Proc Am Soc Clin Oncol, 17, 398a
O'Reilly, 1998, A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy, Proc Am Soc Clin Oncol, 17, 627a
O'Shaughnessy, 2000, A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine), Proc Am Soc Clin Oncol, 19, 400
Michaud, 2000, Improved therapeutic index with lower dose capecitabine in metastatic breast cancer patients, Proc Am Soc Clin Oncol, 19, 402
Canobbio, 1989, Phase II study of Navelbine in advanced breast cancer, Semin Oncol, 16, 33
Degardin, 1994, Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer, Ann Oncol, 5, 423, 10.1093/oxfordjournals.annonc.a058873
Romero, 1994, Vinorelbine as first-line chemotherapy for metastatic breast carcinoma, J Clin Oncol, 12, 336, 10.1200/JCO.1994.12.2.336
Marty, 1992, A review of the antitumour activity of vinorelbine in breast cancer, Drugs, 44, 29, 10.2165/00003495-199200444-00004
Vogel, 1999, Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older, Ann Oncol, 10, 397, 10.1023/A:1008364222793
Ibrahim, 1996, Phase I study of Navelbine (vinorelbine) administered by 96-hour infusion in metastatic breast cancer patients, Breast Cancer Res Treat, 41, 511a
Livingston, 1997, Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer, J Clin Oncol, 15, 1395, 10.1200/JCO.1997.15.4.1395
Burstein, 2000, Herceptin and vinorelbine for Her2-positive metastatic breast cancer: a phase II study, Proc Am Soc Clin Oncol, 19, 392
Hoff, 1996, Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team, Invest New Drugs, 14, 265, 10.1007/BF00194529
Carmichael, 1995, Advanced breast cancer: a phase II trial with gemcitabine, J Clin Oncol, 13, 2731, 10.1200/JCO.1995.13.11.2731
Chlebowski, 1989, Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group, Br J Cancer, 59, 227, 10.1038/bjc.1989.46
Joensuu, 1998, Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial, J Clin Oncol, 16, 3720, 10.1200/JCO.1998.16.12.3720
Holmes, 1996, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer, J Clin Oncol, 14, 2713, 10.1200/JCO.1996.14.10.2713
Holmes, 1995, Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma, Semin Oncol, 22, 9
O'Shaughnessy, 1994, Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer, Semin Oncol, 21, 19
Gianni, 1995, Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study, J Clin Oncol, 13, 2688, 10.1200/JCO.1995.13.11.2688
Pluzanska, 1999, Phase III multicenter trial comparing Taxol/doxorubicin (AT) vs 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer, Breast Cancer Res Treat, 57, 21a
Sparano, 1999, Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer, J Clin Oncol, 17, 880, 10.1200/JCO.1999.17.3.880
Carmichael, 1997, A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee, Semin Oncol, 24, S44
Catimel, 1996, Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety, Semin Oncol, 23, 24
Luck, 1997, Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer, Semin Oncol, 24, S35
Conte, The Italian Experience: Activity and Safety of Paclitaxel Plus Epirubicin in the Treatment of Advanced Breast Cancer, Abstracts of Paclitaxel (Taxol)—Current Practices and Future Directions in Breast Cancer Management—London, September 16, 1995;11-12.
Conte, 1996, A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer, Semin Oncol, 23, 28
Luck, 2000, Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group, Proc Am Soc Clin Oncol, 19, 280
Bozec, 1997, Docetaxel (D) in combination with doxorubicin (Dx) (AT) and with cyclophosphamide (CTX) (TAC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC): high activity and absence of cardiotoxicity, Proc Am Soc Clin Oncol, 16, A566
Lembersky, 2000, Phase II trial of doxorubicin and docetaxel for locally advanced and metastatic breast cancer: preliminary results from NSABP BP-57, Proc Am Soc Clin Oncol, 19, 403
Nabholtz, 1999, Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer, Semin Oncol, 26, 7
Pagani, 2000, Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study, Ann Oncol, 11, 985, 10.1023/A:1008392927656
Perez, 2000, A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma, Cancer, 88, 124, 10.1002/(SICI)1097-0142(20000101)88:1<124::AID-CNCR17>3.0.CO;2-F
Sawada, 1998, Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts, Clin Cancer Res, 4, 1013
O'Shaughnessy, 2000, Results of a large phase III trial of Xeloda/ Taxotere combination therapy vs Taxotere monotherapy in metastatic breast cancer patients, Breast Cancer Res Treat, 64, 381
Spielmann, 1994, Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer, J Clin Oncol, 12, 1764, 10.1200/JCO.1994.12.9.1764
Norris, 2000, Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8, J Clin Oncol, 18, 2385, 10.1200/JCO.2000.18.12.2385
Dieras, 1996, Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method, J Clin Oncol, 14, 3097, 10.1200/JCO.1996.14.12.3097
Hryniuk, 1984, The importance of dose intensity in chemotherapy of metastatic breast cancer, J Clin Oncol, 2, 1281, 10.1200/JCO.1984.2.11.1281
Rahman, 1997, Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer, J Clin Oncol, 15, 3171, 10.1200/JCO.1997.15.10.3171
Stadtmauer, 2000, High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer—reply, N Engl J Med, 343, 440
Esteva, 1998, Monoclonal Antibody-Based Therapy of Cancer, 309
Ross, 1999, The Her-2/neu oncogene: prognostic factor, predictive factor and target for therapy, Semin Cancer Biol, 9, 125, 10.1006/scbi.1998.0083
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Pauletti, 2000, Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry, J Clin Oncol, 18, 3651, 10.1200/JCO.2000.18.21.3651
Niehans, 1993, Stability of Her-2/neu expression over time and at multiple metastatic sites, J Natl Cancer Inst, 85, 1230, 10.1093/jnci/85.15.1230
Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease, J Clin Oncol, 17, 2639, 10.1200/JCO.1999.17.9.2639
Vogel, 2000, First-line, non-hormonal, treatment of women with Her2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-Her2 antibody), Proc Am Soc Clin Oncol, 19, 275a
Slamon, 1998, Addition of Herceptin (Humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial, Proc Am Soc Clin Oncol, 17, 377a
Norton, 1999, Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-Her2 monoclonal antibody Herceptin (H) in Her2-overexpressing (Her2+) metastatic breast cancer (MBC), Proc Am Soc Clin Oncol, 18, 483a
Mass, 2000, The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials, Proc Am Soc Clin Oncol, 19, 291a
Seidman, 2000, Final report: Weekly (W) Herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by Her2 immunophenotype [immunohistochemistry (IHC)] and gene amplification (fluorescent in-situ hybridization (FISH), Proc Am Soc Clin Oncol, 19, 319a
Esteva, 1999, Analysis of response to weekly 1 hour Taxol (T) plus Herceptin (H) by immunophenotypic analysis in Her-2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer, Breast Cancer Res Treat, 57, 17a
Fornier, Herceptin in combination with chemotherapy for the treatment of metastatic breast cancer, Semin Oncol
Pusztai, 1999, Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer, Cancer Treat Rev, 25, 271, 10.1053/ctrv.1999.0132
Pouillart, 1999, Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and Doxorubicin/Taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer, Proc Am Soc Clin Oncol, 19, 275a
Nabholtz, 1999, Doxorubicin and docetaxel (AT) is superior to standard doxorubicin and cyclophosphamide (AC) as first line CT for MBC: randomized phase III trial, Breast Cancer Res Treat, 57, 330a